TriSalus Life Sciences, Inc. Income Statement
TLSI|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
TriSalus Life Sciences, Inc. reported $29M in revenue and $30M in net loss for FY2025. Revenue has grown at a 54.1% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.11 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $29.4M | $18.5M | $12.4M |
| Cost of Revenue | $4.1M | $2.6M | $2.3M |
| Gross Profit | $25.3M | $15.9M | $10.1M |
| SG&A Expense | $18.0M | $23.5M | $12.5M |
| R&D Expense | $17.7M | $29.8M | $21.4M |
| Operating Income | -$36.2M | -$54.5M | -$36.4M |
| Interest Expense | - | - | $1.0K |
| Income Tax | $6.0K | $9.0K | $9.0K |
| Net Income | -$30.0M | -$59.4M | -$47.2M |
| EPS (Basic) | -$1.31 | -$6.77 | -$161.55 |
| EPS (Diluted) | -$1.31 | -$6.77 | -$161.55 |
| Shares Outstanding | 31.3M | 26.3M | 347.9K |
| Gross Margin | 86.1% | 85.9% | 81.8% |
| Operating Margin | -122.9% | -294.3% | -293.9% |
| Profit Margin | -102.1% | -320.7% | -380.6% |